<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01312766</url>
  </required_header>
  <id_info>
    <org_study_id>10EU/hMG02</org_study_id>
    <secondary_id>2010-021021-13</secondary_id>
    <nct_id>NCT01312766</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study in in Vitro Fertilisation (IVF) Patients</brief_title>
  <official_title>Safety and Efficacy Study Comparing a New hMG Formulation (hMG-IBSA) to a Reference Product (Menopur®) in Patients Undergoing Ovarian Stimulation for in Vitro Fertilisation (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the non-inferiority study is to evaluate the clinical efficacy and the safety
      of two different subcutaneous hMG preparations when administered to patients undergoing
      controlled ovarian stimulation for IVF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total Number of Oocytes Retrieved</measure>
    <time_frame>up to 24 days after treatment start</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean hMG Dose (Total);</measure>
    <time_frame>up to 22 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Quality (Percentage of Patients With at Least One Top Quality Embryo)</measure>
    <time_frame>up to 28 days after treatment start</time_frame>
    <description>Assessed by counting the total number of embryos obtained, the number of embryos transferred, frozen and discarded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive b-hCG Test</measure>
    <time_frame>up to 5 weeks after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Controlled Ovarian Stimulation Duration (Days)</measure>
    <time_frame>up to 23 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>17-β Estradiol (E2) Serum Concentration on the Monitoring Day Before hCG Injection;</measure>
    <time_frame>up to 23 days after treatment start</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implantation Rate</measure>
    <time_frame>10-11 weeks after embryo transfer</time_frame>
    <description>defined as the mean of the total number of implanted embryos (presence of gestational sac assessed by ultrasound) divided by the total number of transferred embryos x 100;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate,</measure>
    <time_frame>10 - 11 weeks after embryo transfer</time_frame>
    <description>defined as a pregnancy showing ultrasound embryonic heart activity at 10 - 11 weeks after embryo transfer;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Mature (Grade III Metaphase II) Oocytes Retrieved.</measure>
    <time_frame>at the end of the stimulation.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio Mature/Total Number of Oocytes Retrieved.</measure>
    <time_frame>at the end of the stimulation.</time_frame>
    <description>Percentage of retrieved oocytes considered to be mature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Inseminated Oocytes (IVF and ICSI)</measure>
    <time_frame>on the day of oocyte retrieval</time_frame>
    <description>number of oocytes that were inseminated via IVF or injected via ICSI technique.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Cleaved Embryos</measure>
    <time_frame>two days after insemination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>9 months after treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">270</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>hMG-IBSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>New hMG preparation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Menopur</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menotropins</intervention_name>
    <description>Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
    <arm_group_label>hMG-IBSA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menotropins</intervention_name>
    <description>Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
    <arm_group_label>Menopur</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing ovarian stimulation for IVF with the following characteristics:

               -  Able and willing to sign the Patient Consent Form and adhere to the study
                  visitation schedule

               -  &gt;18 and &lt;40 years old

               -  BMI between 18 and 30 kg/m2

               -  less than 3 previously completed IVF cycles (i.e. completed cycle = egg recovery)

               -  basal FSH &lt;10 IU/L and E2 &lt;80 pg/ml (~290 pmol/l)

               -  Within 12 months of the beginning of the study, uterine cavity consistent with
                  expected normal function as assessed through transvaginal ultrasound,
                  hysterosalpingogram, sonohysterogram or hysteroscopic examination

               -  Successful down-regulation performed with a standard GnRH-Agonist long protocol
                  (Criteria for successful down-regulation: endometrial thickness &lt; 7mm or serum E2
                  level &lt;50 pg/ml (~185 pmol/l).

        Exclusion Criteria:

          -  age &lt;18 and &gt;40 years

          -  primary ovarian failure or women known as poor responders (i.e. requiring more than
             225 IU of hMG as a starting dose in previous treatment cycles or having less than 3
             oocytes retrieved, or with a pre-ovulatory E2 serum concentration &lt;500pg/ml (~1800
             pmol/l))

          -  PCOS

          -  one or both ovaries inaccessible for oocyte retrieval

          -  ovarian cysts &gt;10 mm

          -  hydrosalpinx that have not been surgically removed or ligated;

          -  stage 3 or 4 endometriosis

          -  oocyte donation

          -  implantation of previously frozen embryos

          -  patients affected by pathologies associated with any contraindication of being
             pregnant

          -  hypersensitivity to the study medication

          -  abnormal bleeding of undetermined origin

          -  uncontrolled thyroid or adrenal dysfunction

          -  neoplasias

          -  severe impairment of renal and/or hepatic function

          -  use of concomitant medications that might interfere with study evaluations (e.g.
             non-study hormonal medications, prostaglandin inhibitors, psychotropic agents)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique De Ziegler, MD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Cochin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fertility clinic at Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense Universitetshospital</name>
      <address>
        <city>Odense</city>
        <state>Odensee C</state>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Cochin - Saint Vincent de Paul</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Dept. Obstetric and Gynaecology, Semmelweiss University</name>
      <address>
        <city>Budapest</city>
        <zip>1088</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <state>BS</state>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Fertility Services</name>
      <address>
        <city>Aldridge</city>
        <state>West Midlands</state>
        <zip>WS9 8LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2011</study_first_posted>
  <results_first_submitted>February 28, 2014</results_first_submitted>
  <results_first_submitted_qc>July 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 15, 2014</results_first_posted>
  <last_update_submitted>June 10, 2016</last_update_submitted>
  <last_update_submitted_qc>June 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>hMG-IBSA</title>
          <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
        <group group_id="P2">
          <title>Menopur</title>
          <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="135"/>
                <participants group_id="P2" count="135"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>hMG-IBSA</title>
          <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
        <group group_id="B2">
          <title>Menopur</title>
          <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="135"/>
            <count group_id="B2" value="135"/>
            <count group_id="B3" value="270"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="4.0"/>
                    <measurement group_id="B2" value="33.0" spread="4.1"/>
                    <measurement group_id="B3" value="33.1" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="135"/>
                    <measurement group_id="B2" value="135"/>
                    <measurement group_id="B3" value="270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total Number of Oocytes Retrieved</title>
        <time_frame>up to 24 days after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Oocytes Retrieved</title>
          <units>number of oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.6" spread="6.6"/>
                    <measurement group_id="O2" value="9.7" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>The one-way Analysis of Variance with Least-Squares means was performed to calculate the 95% Confidence Interval of the difference between the two treatments. If the lower bound of the 95% Confidence Interval of the difference between means (hMG-IBSA minus Menopur®) was greater than -2.1, then hMG-IBSA would be considered to be not-inferior to the comparator.</non_inferiority_desc>
            <p_value>0.012</p_value>
            <method>ANOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.43</ci_lower_limit>
            <ci_upper_limit>3.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean hMG Dose (Total);</title>
        <time_frame>up to 22 days after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean hMG Dose (Total);</title>
          <units>Internationa Units (IU)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2171.4" spread="980"/>
                    <measurement group_id="O2" value="2303.6" spread="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.25</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Quality (Percentage of Patients With at Least One Top Quality Embryo)</title>
        <description>Assessed by counting the total number of embryos obtained, the number of embryos transferred, frozen and discarded.</description>
        <time_frame>up to 28 days after treatment start</time_frame>
        <population>The population analysed corresponds to the patients who had at least one embryo to be analysed (i.e 120 participants in the hMG-IBSA group and 123 in the Menopur group). Of this, 119 in the hMG-IBSA group and 121 in the Menopur group underwent embryo transfer.</population>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Quality (Percentage of Patients With at Least One Top Quality Embryo)</title>
          <description>Assessed by counting the total number of embryos obtained, the number of embryos transferred, frozen and discarded.</description>
          <population>The population analysed corresponds to the patients who had at least one embryo to be analysed (i.e 120 participants in the hMG-IBSA group and 123 in the Menopur group). Of this, 119 in the hMG-IBSA group and 121 in the Menopur group underwent embryo transfer.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.3" spread="1.74"/>
                    <measurement group_id="O2" value="63.3" spread="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Positive b-hCG Test</title>
        <time_frame>up to 5 weeks after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Positive b-hCG Test</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.7"/>
                    <measurement group_id="O2" value="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Controlled Ovarian Stimulation Duration (Days)</title>
        <time_frame>up to 23 days after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Controlled Ovarian Stimulation Duration (Days)</title>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.3"/>
                    <measurement group_id="O2" value="10.6" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>17-β Estradiol (E2) Serum Concentration on the Monitoring Day Before hCG Injection;</title>
        <time_frame>up to 23 days after treatment start</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>17-β Estradiol (E2) Serum Concentration on the Monitoring Day Before hCG Injection;</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2613.8" spread="1531.6"/>
                    <measurement group_id="O2" value="2364.0" spread="1441.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Implantation Rate</title>
        <description>defined as the mean of the total number of implanted embryos (presence of gestational sac assessed by ultrasound) divided by the total number of transferred embryos x 100;</description>
        <time_frame>10-11 weeks after embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Implantation Rate</title>
          <description>defined as the mean of the total number of implanted embryos (presence of gestational sac assessed by ultrasound) divided by the total number of transferred embryos x 100;</description>
          <units>percentage of embryos transferred</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="41.0"/>
                    <measurement group_id="O2" value="28.2" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate,</title>
        <description>defined as a pregnancy showing ultrasound embryonic heart activity at 10 – 11 weeks after embryo transfer;</description>
        <time_frame>10 – 11 weeks after embryo transfer</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate,</title>
          <description>defined as a pregnancy showing ultrasound embryonic heart activity at 10 – 11 weeks after embryo transfer;</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="37.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Mature (Grade III Metaphase II) Oocytes Retrieved.</title>
        <time_frame>at the end of the stimulation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Mature (Grade III Metaphase II) Oocytes Retrieved.</title>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" spread="6.0"/>
                    <measurement group_id="O2" value="8.2" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ratio Mature/Total Number of Oocytes Retrieved.</title>
        <description>Percentage of retrieved oocytes considered to be mature.</description>
        <time_frame>at the end of the stimulation.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Ratio Mature/Total Number of Oocytes Retrieved.</title>
          <description>Percentage of retrieved oocytes considered to be mature.</description>
          <units>percentage of total oocytes retrieved</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Inseminated Oocytes (IVF and ICSI)</title>
        <description>number of oocytes that were inseminated via IVF or injected via ICSI technique.</description>
        <time_frame>on the day of oocyte retrieval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Inseminated Oocytes (IVF and ICSI)</title>
          <description>number of oocytes that were inseminated via IVF or injected via ICSI technique.</description>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.8" spread="5.9"/>
                    <measurement group_id="O2" value="8.4" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Cleaved Embryos</title>
        <time_frame>two days after insemination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cleaved Embryos</title>
          <units>embryos</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="3.8"/>
                    <measurement group_id="O2" value="4.8" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rate</title>
        <time_frame>9 months after treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>hMG-IBSA</title>
            <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
          <group group_id="O2">
            <title>Menopur</title>
            <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="135"/>
                <count group_id="O2" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.6"/>
                    <measurement group_id="O2" value="36.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>hMG-IBSA</title>
          <description>New hMG preparation.
Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
        <group group_id="E2">
          <title>Menopur</title>
          <description>Menotropins: Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Vestibular disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>peritoneal heamorrage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Headacje</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Incomplete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Abortion Missed</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Abortion threatened</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>OHSS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Ovarina torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="23" subjects_affected="18" subjects_at_risk="135"/>
                <counts group_id="E2" events="18" subjects_affected="14" subjects_at_risk="135"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="33" subjects_affected="21" subjects_at_risk="135"/>
                <counts group_id="E2" events="32" subjects_affected="20" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flushes</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="135"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="135"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Barbara Cometti, Senior Clinical Research Manager, IBSA</name_or_title>
      <organization>IBSA Institut Biochimique SA</organization>
      <phone>+41 58 360 10 00</phone>
      <email>barbara.cometti@ibsa.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

